Erythropoiesis-stimulating agents (ESAs) are a very effective treatment for reducing the need for transfusions in patients affected by anemia and either chronic kidney disease (CKD) or cancer. However ...

Please provide your email address to receive an email when new articles are posted on . Patients switched to oral vadadustat had hemoglobin levels similar to those on a long-acting ...

Radiation Oncology Services in the Modern Era: Evolving Patterns of Usage and Payments in the Office Setting for Medicare Patients From 2000 to 2010 The SEER-Medicare database was used to identify ...

Phase II trial comparing darbepoetin alfa every 3-week versus weekly epoetin alfa for the treatment of chemotherapy-induced anemia Meta-analyses RADAR and Cochrane Collaboration 2008: Identified ...

June 10, 2008 (Chicago, Illinois) — A provocative new study has shown that erythropoiesis-stimulating agents (ESAs) might have an effect not only on red blood cells but on tumor blood vessels as well.

Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs). Patients with lower-risk myelodysplastic ...

DENVER—Angiotensin receptor blocker (ARB) treatment may affect response to erythropoiesis-stimulating agents (ESAs) in hemodialysis (HD) patients by disturbing iron homeostasis, Japanese researchers ...

Your blood carries oxygen to all of the cells in your body. When there are problems with red blood cells, you can feel weak and tired and may have to take medicines or receive blood transfusions to ...

Declines in ESA hyporesponsiveness are significantly associated with increased malignancy risk in patients with CKD not on dialysis. A prospective study has identified an association between ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved luspatercept-aamt as first-line treatment for anemia among certain adults with myelodysplastic ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win ...